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Abstract
A new method of analysis has been developed and validated for the determination of meloxicam
in egg whites and yolks. Following a liquid extraction for the whites and a solid phase extraction
for the yolks, samples were separated on an XBridge C18 column and quantified using ultraviolet
detection at 360 nm. The mobile phase was a mixture of water with glacial acetic acid and aceto-
nitrile, with a flow rate of 1mL/min. The procedure produced a linear graph over the concentration
range 5–1500 ng/mL with a lower limit of quantification of 5 ng/mL. Intra- and inter-assay variabil-
ity was 10% or less for both the whites and yolks. The average recovery for whites was 96% and
the average recovery in yolks was 97%.
Introduction
With the increasing popularity of backyard poultry ownership, ve-
terinarians are faced with how to treat these animals with regard to
drug withdrawal times for egg consumption. Veterinary drugs and
feed additives can be absorbed by the digestive tract of laying hens
and transferred to the egg. Physicochemical characteristics of these
compounds determine their pharmacokinetic behavior and distri-
bution to and within eggs. A recent review describes allowable
medications for use in egg-laying poultry; however, few drugs have
recommended doses or withdrawal times for use in laying hens (1).
Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-1, 3-thiazol-2-yl)-1,
1-dioxo-1λ6, 2-benzothiazine-3-carboxamide) is a non-steroidal anti-
inflammatory drug (NSAID) that is commonly used in avian medicine.
NSAIDs are generally used to treat painful conditions such as injuries,
cancer surgery and dental infections. Meloxicam preferentially inhibits
the cyclooxygenase-2 (COX-2) enzyme over COX-1. The ability to
only inhibit the inflammatory COX-2 proved to be revolutionary for
pain management. The introduction of COX-2 preferential NSAIDs
has reduced stomach and intestinal side effects. A commercially
liquid form is readily available and is easily administered to birds.
A recent publication from Marmulak et al. (1) reported that the
Food Animal Residue Avoidance Databank received more requests
for egg withdrawal intervals for hens following meloxicam admin-
istration than for any other drug (1). Although one study examined
meloxicam in chickens following intravenous administration (2),
no published pharmacokinetic studies are available to aid in re-
commendations regarding dosing or withdrawal times for oral me-
loxicam administration.
Meloxicam levels in plasma have been determined using a num-
ber of analytical methods (2–17). Although mass spectrometry (3, 4,
12, 16) can produce the highest detection sensitivity, it may not be
readily available in all laboratories and is expensive. The most eco-
nomical method is high performance liquid chromatography with
ultraviolet detection (HPLC–UV). In order to obtain a suitable limit
of quantification (LOQ) for the determination of meloxicam in bio-
logical samples, several different processes have been used. Some of
the methods employed include liquid–liquid extractions using
diethyl ether (2, 5, 7, 9, 14), protein precipitation (6, 8, 15), pre-
column enrichment (10, 11, 17) and solid phase extraction (13). To
the authors’ knowledge, there are no methods for the determination
of meloxicam in eggs. Therefore, the aim of this paper was to
describe a sensitive, specific, and accurate method for determining
meloxicam in both egg whites and yolks using HPLC.
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Experimental
Instrumentation and reagents
The chromatography system consisted of a 2695 separation module
and a 2487 ultraviolet detector (Waters, Milford, MA). Separation
was achieved on a Waters XBridge C18 column (4.6 × 250mm,
5 µm) preceded by a 5 µm XBridge C18 guard column (3.9 ×
20mm). The mobile phase was an isocratic mixture of A: 990mL
water with 10mL 85% glacial acetic acid, pH 3.0 with 1M sodium
hydroxide and B: acetonitrile. This was mixed at a ratio of 50% A
and 50% B throughout the entire run. All solutions were filtered
through a 0.22 µm filter and degassed before their use. The water
was replaced on a daily basis. The flow rate was 1.0mL/min, and
the column and autosampler temperature were ambient which was
23°C. The ultraviolet detector was set at a wavelength of 360 nm.
Meloxicam (Figure 1) was purchased from Toronto Research
Chemicals (Ontario, Canada) and was 99% pure. Piroxicam
(Figure 1), which was the internal standard (IS) (99% purity), was
purchased from US Pharmacopeia (Rockville, MD, USA). All
reagent grade chemicals and solvents were purchased from Fisher
Scientific (Pittsburg, PA, USA). Water (18.2MΩ) was obtained from
a Barnstead Nanopure Infinity (Dubuque, IA, USA) ultrapure water
system.
Preparation of calibration standards
Five milligrams each of meloxicam or piroxicam were weighed using
a Sartorius Microbalance (Elk Grove, IL, USA) and dissolved in
methanol to produce stock concentrations of 100 µg/mL. Dilutions
of the meloxicam and piroxicam stock standards were prepared in
methanol to produce 0.1, 1, 5 and 10 µg/mL working stock solu-
tions. Standards were aliquoted into 2-mL vials to prevent evapor-
ation and cross contamination. All solutions were protected from
light in bottles wrapped in aluminum foil and stored at −20°C. By
comparing standard areas over time, it was determined that solu-
tions were stable for a minimum of 6 months.
For preparation of calibration standards and quality control
samples, appropriate volumes of stock solutions were placed in
screw top tubes and evaporated with nitrogen gas then untreated
egg white or yolk was added.
Sample preparation
Meloxicam was extracted from egg whites using a modified version
of the plasma method developed by Cox et al. (18). The white and
yolk were separated then 1mL of white was placed in a 15mL
screw cap tube. An aliquot of 75 µL of piroxicam (5 µg/mL) was
added followed by 1mL of 1M hydrochloric acid (HCl) and 5mL
of chloroform. The tubes were vortex-mixed at high speed for 60 s
followed by centrifugation for 20min at 1000 × g. The supernatant
was removed and placed in a 16 × 100mm glass test tube (15mL
capacity) and evaporated to dryness with nitrogen. Samples were re-
constituted in 300 µL of mobile phase, vortex-mixed and the super-
natant was placed in total recovery chromatographic vials then
100 µL injected into the system.
After separation from the white, 1 mL of yolk was placed in a
15mL screw top tube. An aliquot of 75 µL of piroxicam (5 µg/mL)
was added followed by 200 µL of 1M HCl and 2mL of acetonitrile.
The tubes were vortexed for 30 s followed by centrifugation for
20min at 1000 × g. The supernatant was removed and placed in a
16 × 100 glass test tube. The extraction process on the yolk protein
pellet was repeated and the supernatants were combined, and then
evaporated until roughly 100 µL remain. Methanol (100 µL) and
water (900 µL) were added to the tube and vortexed for 10 s. The
tubes were centrifuged for 20min at 1000 × g. The supernatant was
removed and added to a prewet (1 mL methanol, 1 mL water) Oasis
HLB 3 cc extraction cartridge (Waters, Milford, MA, USA). The
cartridge was washed with 5% methanol in water and the sample
was eluted with 2mL of acetonitrile water (90:10, v/v). The eluent
was evaporated to dryness with nitrogen and reconstituted in 300 µL
of mobile phase, vortex-mixed and the supernatant was placed in
total recovery chromatographic vials, then 100 µL injected into the
system.
Method validation
The method was validated according to the Guidelines for
Bioanalytical Method Validation published by the Food and Drug
Administration (19). Validation of the method was carried out using
QC samples. All of the QC samples and calibration curves were pre-
pared in egg white and yolk matrices. The validation process looked
at accuracy, precision, selectivity, sensitivity, reproducibility and
stability.
Selectivity
Selectivity was determined by injecting blank egg whites and yolks
from six different chickens to confirm no interfering peaks around
the retention time of both meloxicam and piroxicam, the IS.
Calibration curve, linearity and quality control samples
The final concentrations for the calibration standard curve were 5,
10, 25, 50, 100, 250, 500, 800, 1000 and 1500 ng/mL. The calibra-
tion curve was constructed by using the ratio of the peak area of the
analyte divided by the peak area of the IS versus the concentration
and obtained on five different days. Linearity was assessed by linear
regression analysis and expressed as the coefficient of determination
(r2). The standard deviations of the slope, intercepts and regression
coefficient were calculated. The QC samples were prepared in a
similar manner as the calibration standards at four different levels,
15, 75, 350 and 1200 ng/mL. The acceptance criterion for each
back-calculated standard was 15% deviation from the nominal va-
lue except lower (LLOQ), which was set at 20%.Figure 1. Structures of meloxicam and piroxicam.
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Accuracy, precision and recovery
The precision and accuracy of the assay were determined using QC
samples of known meloxicam concentrations (15, 75, 350 and
1200 ng/mL), which were processed freshly each validation day.
Five replicates of each QC were analyzed during the same day and
on five different days, and the intra- and inter-assay means, stand-
ard deviation (SD) and coefficient of variation (CV) were calcu-
lated. Recoveries were calculated as the measured concentrations
divided by the expected concentrations and expressed as a percent-
age (19). Equations for accuracy, precision and recovery are listed
below.
Accuracy equation: (Measured concentration/added concentration)
× 100%
Precision equation: Absolute standard deviation (SD):






relative standard deviation (RSD) or coefficient
of variation (CV):
RSD (%) = (SD/x̅)100
Recovery equation: (X/µ) × 100%,
where, X = measured concentration and
µ = added concentration.
Results
Selectivity
Endogenous components from either the white or yolk did not inter-
fere with the elution of the compounds of interest. Six different
blank whites and yolks were used in the pre-validation process.
Figure 2 shows chromatograms of a (A) blank white, (B) a 75 ng/mL
spiked white standard, (C) a white sample from a chicken 1 day
after 1 mg/kg oral meloxicam administration, (D) a blank yolk, (E) a
350 ng/mL spiked yolk standard and (F) a yolk sample 3 days after
1mg/kg oral meloxicam administration. Retention times were
7.7min for meloxicam and 6.0min for piroxicam.
Calibration curves, precision, accuracy and linearity
The egg white and yolk peak area ratio (area of meloxicam divided
by IS area) versus concentration was plotted which produced a lin-
ear curve for the concentration range used (5–1500 ng/mL) with the
correlation coefficients ranging from 0.9993 to 0.9996. The mean
slopes, intercepts and r2 values are reported in Tables I and III. A
typical linear equation for the egg white calibration curve was y =
0.0022x −0.0071 while a typical curve for the egg yolk calibration
curve was y = 0.0023x + 0.0050 where y represents the peak area
ratios of meloxicam to IS and x represents the concentration of me-
loxicam in nanograms per milliliter.
All values of accuracy and precision were within the recom-
mended limits. Intra-assay precision ranged from 5.1 to 8.3% for
egg whites and 4.9 to 9.0% for egg yolks. The inter-assay precision
ranged from 3.2 to 6.4% for whites and 5.7 to 10.1 for yolks. These
precision values are well below the set ±15% for all quality control
samples as shown in Tables I through IV. The intra-assay accuracy
ranged from 96 to 100% for whites and 100–106% for yolks. The
inter-assay accuracy for whites ranged from 93 to 100% and for
yolks 100 to 106%.
Recovery, LLOQ and stability
The recovery of meloxicam was determined by comparing the peak
areas of extracted analytes with that of the directly injected standard
solutions. The average recovery of meloxicam from the four egg
white QC concentrations ranged from 95–98% while the average
recovery from egg yolks ranged from 94 to 98%. The average recov-
ery of piroxicam was 93 and 96% from egg whites and yolks,
respectively.
The LLOQ was 5 ng/mL for both egg whites and yolks, which
represents a peak approximately five times baseline noise.
Testing of short-term stability of the quality control standards
for egg whites indicated that there was a 2% loss of drug after
24 h in the autosampler and no loss after 24 h in the refrigerator
at 4°C. For egg yolks there was no loss of meloxicam after 24 h in
the autosampler and a 5% loss after 24 h in the refrigerator.
Samples in our studies were not frozen. The eggs were collected
and then stored in the refrigerator until analysis which was within
10 days. On the day of analysis, the white and yolk were sepa-
rated and analyzed on the same day, then both egg white and
yolk samples were stored at −80°C. After one freeze–thaw cycle
there was an average meloxicam loss of 30% in egg yolks and a
7% loss in egg whites.
Discussion
We have developed and validated the first method for quantification
of meloxicam in both egg whites and yolks using reverse phase sep-
aration and UV detection. Various methods have been developed for
the determination of meloxicam in plasma but to the authors’
knowledge none were available for eggs.
Having previously developed and validated a method for meloxi-
cam analysis in plasma (18), that method was applied to both egg
whites and yolks with modifications. The application of the method
to egg whites proved successful while the application to the yolks
was not. The average recovery from whites was 96% while the
recovery from yolks was approximately 10%. The method for egg
whites was modified by increasing the sample size since sample
quantity was not an issue with eggs. The 1:1 ratio for sample and
hydrochloric acid produced the greatest recovery of meloxicam from
plasma therefore the same ratio was applied to the egg white sam-
ples. Two different volumes of chloroform were initially tried; 8 and
5mL. The recovery for the two volumes used were equal therefore
5mL was used. Any volume <5mL resulted in a decrease in the
recovery.
Since the chloroform/hydrochloric acid extraction was not suc-
cessful in extracting meloxicam from the yolks, other organic sol-
vents and mixtures were used including acetonitrile, methanol,
perchloric acid:chloroform, formic acid:acetonitrile, perchloric acid:
acetonitrile and methanol:chloroform. All were found to produce
either lower recoveries or poor peak resolution. Solid phase extrac-
tion was then applied to the yolk samples using Oasis PRiME HLB
(Waters, Milford, MA, USA) cartridges; however, the recovery using
these cartridges was less than 20% even with varied wash and elu-
tion volumes and solutions. Oasis HLB cartridges were then used
and the hydrophilic–lipophilic balanced copolymer enabled high
recoveries for both meloxicam and piroxicam from egg yolks. Once
an appropriate cartridge was selected, we also looked at various
wash solutions including 2.5, 5 and 10% methanol. The 10% solu-
tion caused a decrease in recovery and the 2.5% solution produced
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interfering peaks. The use of 2 mL of wash solution also decreased
the recovery of meloxicam; therefore 1 mL of wash solution was
used. The elution composition of 90:10 acetonitrile:methanol was
part of a standard protocol recommended by the manufacturer
which worked well for the yolk application and was not varied.
The amount of hydrochloric acid and acetonitrile used in the
Figure 2. Chromatograms for a (A) blank egg white, (B) an egg white standard spiked with 75 ng/mL meloxicam and IS, (C) an egg white sample from a chicken
1 day after a 1mg/kg oral meloxicam administration, (D) a blank egg yolk, (E) an egg yolk standard spiked with 350 ng/mL of meloxicam and IS and (F) an egg
yolk sample 3 days after a 1mg/kg oral meloxicam administration.
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protein precipitation phase were also optimized. If no acid was
used the meloxicam recovery was less than 10%. We looked at the
addition of 200, 300 and 400 µL amounts of 1M HCl and found
that there was very little change in meloxicam recovery; therefore,
we chose 200 µL. The amount of acetonitrile used in the precipita-
tion phase was also varied and the amounts ranged from 2 to
4 mL. There was very little change in the recovery of meloxicam
thus we chose 2 mL.
Figure 2. Continued
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The recovery and LOQ are more than adequate for use in the
determination of meloxicam in eggs. There is a 2% or less, sample
loss in whites and 5% or less sample loss in yolks after storage in
either the autosampler or refrigerator; therefore, if there were a
power or equipment failure, samples could be reanalyzed. The add-
ition of piroxicam as an IS allows for the correction of intra- and
inter-assay variability.
Conclusion
This is the first method developed for the analysis of meloxicam in
egg whites and yolks. More people are choosing to keep live poultry
as a way to locally produce food in a humane manner. Veterinarians
are faced with how to treat these animals with regard to drug with-
drawal times for egg consumption, thus the need for analytical meth-
odology to aid in determining these times. This analytical procedure
was validated in terms of recovery, linearity, LLOQ, precision and
accuracy. Our results indicate the method is sensitive, accurate and
reproducible, providing consistent quantification of meloxicam. This
method has been used successfully to determine meloxicam in both egg
whites and yolks in two studies conducted at this institution (20)
(Souza et al., submitted for publication). In the studies egg concentra-
tions of meloxicam following a single oral dose and following oral dos-
ing at 1mg/kg every 12 h for a total of nine doses (5 days) were
determined. Meloxicam was detected in egg whites up to 4 days and in
egg yolks up to 8 days after single dosing. While drug was detected in
egg whites up to 3 days and in egg yolks up to 8 days after multiple
doses. Based on these results a 2-week withdrawal time should be
adequate to avoid drug residues in eggs meant for consumption.
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